JP2024522292A - ナトリウムチャネルのモジュレーターとしてのｎ－（ヒドロキシアルキル（ヘテロ）アリール）テトラヒドロフランカルボキサミド - Google Patents

ナトリウムチャネルのモジュレーターとしてのｎ－（ヒドロキシアルキル（ヘテロ）アリール）テトラヒドロフランカルボキサミド Download PDF

Info

Publication number
JP2024522292A
JP2024522292A JP2023574395A JP2023574395A JP2024522292A JP 2024522292 A JP2024522292 A JP 2024522292A JP 2023574395 A JP2023574395 A JP 2023574395A JP 2023574395 A JP2023574395 A JP 2023574395A JP 2024522292 A JP2024522292 A JP 2024522292A
Authority
JP
Japan
Prior art keywords
pain
compound
pharma
acceptable salt
ceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023574395A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024522292A5 (enExample
Inventor
エリザベス メアリー ベック，
ロバート プリン，
ジャルディ， ゴルカ エチェバリア
ディーン ステイモス，
イボンヌ シュミット，
ジョセフ ポンティロ，
スティーブン アンドリュー トムソン，
デイビッド マシュー ショー，
ナディア エム． アハマド，
メイレレス， リディオ マルクス カルバーリョ
サラ スケラット，
ルア， サラ エス． ハディダ
ティモシー ドナルド ノイバート，
デニス ジェイムズ ハーレイ，
ジンラン ジョウ，
スティーブン ジョン デュラント，
クリストファー レイ，
アニサ ニザラリ ビラニ，
キリ ノース，
ジェイムズ ドッド，
マイケル エドワード オドネル，
バイラビ ガラン，
ロナルド マーセラス ネグテル，
エワ イウォナ チャデク，
ジョアン ルイーズ ピンダー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Publication of JP2024522292A publication Critical patent/JP2024522292A/ja
Publication of JP2024522292A5 publication Critical patent/JP2024522292A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Furan Compounds (AREA)
JP2023574395A 2021-06-04 2022-06-03 ナトリウムチャネルのモジュレーターとしてのｎ－（ヒドロキシアルキル（ヘテロ）アリール）テトラヒドロフランカルボキサミド Pending JP2024522292A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163196946P 2021-06-04 2021-06-04
US63/196,946 2021-06-04
PCT/US2022/032116 WO2022256622A1 (en) 2021-06-04 2022-06-03 N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels

Publications (2)

Publication Number Publication Date
JP2024522292A true JP2024522292A (ja) 2024-06-13
JP2024522292A5 JP2024522292A5 (enExample) 2025-07-01

Family

ID=82483401

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023574395A Pending JP2024522292A (ja) 2021-06-04 2022-06-03 ナトリウムチャネルのモジュレーターとしてのｎ－（ヒドロキシアルキル（ヘテロ）アリール）テトラヒドロフランカルボキサミド

Country Status (33)

Country Link
US (3) US11827627B2 (enExample)
EP (2) EP4347031B1 (enExample)
JP (1) JP2024522292A (enExample)
KR (1) KR20240031300A (enExample)
CN (1) CN117794920A (enExample)
AR (1) AR126073A1 (enExample)
AU (1) AU2022284886A1 (enExample)
CA (1) CA3221259A1 (enExample)
CL (1) CL2023003625A1 (enExample)
CO (1) CO2023017899A2 (enExample)
CR (1) CR20230586A (enExample)
DK (1) DK4347031T3 (enExample)
DO (1) DOP2023000267A (enExample)
EC (1) ECSP23095485A (enExample)
ES (1) ES3058787T3 (enExample)
FI (1) FI4347031T3 (enExample)
GE (1) GEAP202416430A (enExample)
HR (1) HRP20251504T1 (enExample)
IL (1) IL308953A (enExample)
JO (1) JOP20230316B1 (enExample)
LT (1) LT4347031T (enExample)
MA (1) MA64853B1 (enExample)
MD (1) MD4347031T2 (enExample)
MX (1) MX2023014378A (enExample)
PE (1) PE20241335A1 (enExample)
PL (1) PL4347031T3 (enExample)
PT (1) PT4347031T (enExample)
RS (1) RS67577B1 (enExample)
SI (1) SI4347031T1 (enExample)
SM (1) SMT202500481T1 (enExample)
TW (1) TW202313593A (enExample)
UY (1) UY39800A (enExample)
WO (1) WO2022256622A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3154386A1 (en) 2019-10-17 2021-04-22 Michael Berlin Bifunctional molecules containing an e3 ubiquitine ligase binding moiety linked to a bcl6 targeting moiety
BR112022010924A2 (pt) 2019-12-06 2022-09-06 Vertex Pharma Tetra-hidrofuranos substituídos como moduladores de canais de sódio
SMT202500481T1 (it) 2021-06-04 2026-01-12 Vertex Pharma N-(idrossialchil(etero)aril)tetraidrofuran carbossammidi come modulatori di canali del sodio
WO2023205463A1 (en) 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
KR20250052383A (ko) * 2022-08-24 2025-04-18 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 헤테로시클릭계 화합물, 이의 제조 방법 및 이의 의학적 응용
CN119731169A (zh) * 2022-08-28 2025-03-28 上海汇伦医药股份有限公司 一种钠通道调节剂及其应用
WO2024123815A1 (en) * 2022-12-06 2024-06-13 Vertex Pharmaceuticals Incorporated Process for the synthesis of substituted tetrahydrofuran modulators of sodium channels
EP4647430A4 (en) * 2023-01-06 2026-03-11 Haisco Pharmaceutical Group Co Ltd Tetrahydrothiophene derivative and its use in medicine
WO2024188367A1 (zh) * 2023-03-10 2024-09-19 西藏海思科制药有限公司 一种四氢呋喃衍生物及其在医药上的应用
WO2024217528A1 (zh) * 2023-04-20 2024-10-24 西藏海思科制药有限公司 一种杂环化合物及其在医药上的应用
CN119371405A (zh) 2023-07-26 2025-01-28 上海闻耐医药科技有限公司 多取代吡咯烷类衍生物、其制备方法及用途
WO2025092922A1 (en) * 2023-11-02 2025-05-08 Iongen Therapeutics Co., Ltd. Compounds, compositions and methods thereof
WO2025108234A1 (zh) * 2023-11-20 2025-05-30 四川科伦药物研究院有限公司 化合物、其制备方法及用途
CN120192306A (zh) * 2023-12-21 2025-06-24 武汉熙瑞医药科技有限公司 一种含苯环的多环化合物、其药物组合物及其应用
WO2025162194A1 (zh) * 2024-01-31 2025-08-07 上海汇伦医药股份有限公司 钠通道调节剂新化合物及其应用
WO2025168043A1 (zh) * 2024-02-08 2025-08-14 上海枢境生物科技有限公司 并环类衍生物、制备方法及其用途
CN120040430A (zh) * 2024-02-23 2025-05-27 山东盛迪医药有限公司 一种取代四氢呋喃衍生物的可药用盐、其结晶形式及用途
CN120040429B (zh) * 2024-02-23 2026-03-31 山东盛迪医药有限公司 一种取代四氢呋喃衍生物的结晶形式及其用途
CN117902972B (zh) * 2024-03-19 2024-06-11 深圳创元生物医药科技有限公司 一种2,4-二羟基苯乙酸的制备方法
CN120774914A (zh) * 2024-04-03 2025-10-14 武汉人福创新药物研发中心有限公司 作为Nav1.8抑制剂的四氢呋喃吡啶酮类化合物
CN118388466A (zh) * 2024-04-23 2024-07-26 安润医药科技（苏州）有限公司 作钠通道调节剂的酰胺衍生物及其用途
WO2025252109A1 (zh) * 2024-06-04 2025-12-11 成都苑东生物制药股份有限公司 一种取代四氢呋喃类衍生物、其制备方法及用途
WO2026012382A1 (zh) * 2024-07-10 2026-01-15 海思科医药集团股份有限公司 一种硫杂环戊基衍生物的药物制剂及其在医药上的应用
WO2026030525A1 (en) 2024-07-31 2026-02-05 Vertex Pharmaceuticals Incorporated Zilvetrigine dosage forms and dosing regimens for treating pain
CN119285621B (zh) * 2024-12-13 2025-07-18 嘉兴安帝康生物科技有限公司 作为钠通道调节剂的四氢呋喃甲酰胺类化合物及其在医药上的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020092667A1 (en) * 2018-11-02 2020-05-07 Merck Sharp & Dohme Corp. 2-amino-n-heteroaryl-nicotinamides as nav1.8 inhibitors
JP2020526561A (ja) * 2017-07-11 2020-08-31 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ ナトリウムチャネルのモジュレーターとしてのカルボキサミド

Family Cites Families (431)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4844732A (en) 1985-10-24 1989-07-04 Daicel Chemical Industries Ltd. Pyridine-3-carboxamide derivatives
JPH075555B2 (ja) 1986-02-25 1995-01-25 ダイセル化学工業株式会社 ピリドン−３−カルボキサミドの製法
JPH075554B2 (ja) 1986-02-25 1995-01-25 ダイセル化学工業株式会社 ５−ブロモピリドン−３−カルボキサミド化合物の製法
WO1991000858A1 (en) 1989-07-07 1991-01-24 Schering Corporation Pharmaceutically active compounds
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
MY106399A (en) 1990-07-24 1995-05-30 Pfizer Cephalosporins and homologeus, preparation and pharmaceutical composition
FR2665440B1 (fr) 1990-07-31 1994-02-04 Lipha Nouveaux cycloalkylsulfonamides substitues, procedes de preparation et medicaments les contenant.
JPH05107574A (ja) 1991-03-12 1993-04-30 Mitsui Petrochem Ind Ltd 有機非線形光学材料
AU676993B2 (en) 1991-06-27 1997-04-10 Virginia Commonwealth University Sigma receptor ligands and the use thereof
US5356897A (en) 1991-09-09 1994-10-18 Fujisawa Pharmaceutical Co., Ltd. 3-(heteroaryl)-pyrazololi[1,5-a]pyrimidines
IT1254134B (it) 1992-01-16 1995-09-08 Angeletti P Ist Richerche Bio Oligonucleotidi antisenso chimicamente modificati.
HRP930210A2 (en) 1992-02-25 1995-06-30 Recordati Chem Pharm Heterobicyclic compounds and pharmaceutical preparations containing them
IT1254469B (it) 1992-02-25 1995-09-25 Recordati Chem Pharm Derivati benzopiranici e benzotiopiranici
ATE188379T1 (de) 1992-10-14 2000-01-15 Merck & Co Inc Fibrinogenrezeptor-antagonisten
US5886026A (en) 1993-07-19 1999-03-23 Angiotech Pharmaceuticals Inc. Anti-angiogenic compositions and methods of use
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
GB2300856A (en) 1995-05-16 1996-11-20 Pfizer Ltd Beta-lactam preparation
JP3964478B2 (ja) 1995-06-30 2007-08-22 エーザイ・アール・アンド・ディー・マネジメント株式会社 ヘテロ環含有カルボン酸誘導体及びそれを含有する医薬
AU4153496A (en) 1995-10-20 1997-05-07 Flora Inc. Transdermal delivery of alpha adrenoceptor blocking agents
US5968965A (en) 1996-01-30 1999-10-19 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
AU703203B2 (en) 1996-01-30 1999-03-18 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
FR2746309B1 (fr) 1996-03-22 1998-04-17 Oreal Composition de teinture des fibres keratiniques contenant des pyrazolopyrimidineoxo ; leur utilisation pour la teinture comme coupleurs, procedes de teinture
ATE238328T1 (de) 1996-10-16 2003-05-15 Ribapharm Inc Monozyklische l-nukleoside, analoga und ihre anwendungen
CA2268399C (en) 1996-10-31 2008-08-19 Harbor Branch Oceanographic Institution, Inc. Anti-neurogenic inflammatory compounds and compositions and methods of use thereof
JPH10213820A (ja) 1997-01-31 1998-08-11 Canon Inc 液晶素子及び液晶装置
US5942508A (en) 1997-02-04 1999-08-24 Senju Pharmaceutical Co., Ltd. Method for solubilizing pyridonecarboxylic acid solubilizer thereof and aqueous solution containing solubilized pyridonecarboxylic acid
EP1025857A4 (en) 1997-10-22 2003-11-12 Eisai Co Ltd RETINOIC ACID AGONISTS, PREVENTIVE AND THERAPEUTIC AGENTS FOR NEPHRITES
US6150379A (en) 1997-11-26 2000-11-21 Axys Pharmaceuticals, Inc. Compounds and compositions as anticoagulants
EP1117635A1 (en) 1998-09-30 2001-07-25 The Procter & Gamble Company 2-substituted ketoamides
WO2000025789A1 (en) 1998-10-29 2000-05-11 Merck & Co., Inc. A method of treating endometriosis
PL351470A1 (en) 1999-04-28 2003-04-22 Aventis Pharma Gmbh Tri-aryl acid derivatives as ppar receptor ligands
WO2001012183A1 (en) 1999-08-16 2001-02-22 Merck & Co., Inc. Heterocycle amides as cell adhesion inhibitors
CZ2002959A3 (cs) 1999-09-17 2002-07-17 Millennium Pharmaceuticals, Inc. Inhibitory faktoru Xa
ES2316383T3 (es) 1999-09-17 2009-04-16 Millennium Pharmaceuticals, Inc. Benzamidas e inhibidores relacionados del factor xa.
HK1049672A1 (zh) 1999-10-29 2003-05-23 辉瑞产品公司 潮霉素衍生物
BR0015315A (pt) 1999-11-05 2002-06-25 Sod Conseils Rech Applic Compostos, medicamentos, composições farmacêuticas, utilização de compostos e produtos industriais
TWI284639B (en) 2000-01-24 2007-08-01 Shionogi & Co A compound having thrombopoietin receptor agonistic effect
WO2001064642A2 (en) 2000-02-29 2001-09-07 Cor Therapeutics, Inc. Benzamides and related inhibitors of factor xa
IL151517A0 (en) 2000-03-09 2003-04-10 Aventis Pharma Gmbh Therapeutic uses of ppar mediators
AU2001275881B2 (en) 2000-07-10 2006-04-06 Vertex Pharmaceuticals (San Diego) Llc Ion channel assay methods
JP2004508359A (ja) 2000-09-06 2004-03-18 ニューロゲン　コーポレイション アリール置換テトラヒドロインダゾール、及び、ｇａｂａ−ａ受容体に対するリガンドとしてのそれらの使用
AU2002255473A1 (en) 2000-10-24 2002-09-04 Glaxo Group Limited Process for preparing intermediates of hiv protease inhibitors
JP3786203B2 (ja) 2000-11-04 2006-06-14 アベンティス・フアーマ・リミテッド 置換アルカン酸
EP1217000A1 (en) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
KR20080079341A (ko) 2001-01-16 2008-08-29 아스트라제네카 아베 치료용 헤테로시클릭 화합물
ES2364550T3 (es) 2001-03-05 2011-09-06 E. I. Du Pont De Nemours And Company Agentes de control de plagas de invertebrados de diamidas heterocíclicas.
WO2002083628A1 (en) 2001-04-13 2002-10-24 Boehringer Ingelheim Pharmaceuticals, Inc. 1,4-disubstituted benzo-fused compounds
JP2003034671A (ja) 2001-05-17 2003-02-07 Nippon Nohyaku Co Ltd ベンズアミド誘導体及び農園芸用薬剤並びにその使用方法
US20030175950A1 (en) 2001-05-29 2003-09-18 Mcswiggen James A. RNA interference mediated inhibition of HIV gene expression using short interfering RNA
WO2003070912A2 (en) 2001-06-06 2003-08-28 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF EPIDERMAL GROWTH FACTOR RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2003000245A1 (en) 2001-06-22 2003-01-03 Poseidon Pharmaceuticals A/S Compounds for use in disorders associated with mast cell or basophil activity
CN104744461A (zh) 2001-09-21 2015-07-01 百时美施贵宝公司 含有内酰胺的化合物及其衍生物作为Xa因子的抑制剂
FR2831536A1 (fr) 2001-10-26 2003-05-02 Aventis Pharma Sa Nouveaux derives de benzimidazoles, leur procede de preparation, leur application a titre de medicament, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de kdr
SE0103648D0 (sv) 2001-11-01 2001-11-01 Astrazeneca Ab Therapeutic quinolone compounds
ES2234451T1 (es) 2001-11-14 2005-07-01 Teva Pharmaceutical Industries Ltd. Formas cristalinas y amorfas de losartan potasio y procedimiento para su preparacion.
US20050038035A1 (en) 2001-11-28 2005-02-17 Hisashi Takasugi Heterocyclic amide compounds as apolipoprotein b inhibitors
WO2003048081A2 (en) 2001-12-04 2003-06-12 Bristol-Myers Squibb Company Glycinamides as factor xa inhibitors
WO2003062221A1 (en) 2002-01-22 2003-07-31 E.I. Du Pont De Nemours And Company Diamide invertebrate pest control agents
EP1336602A1 (en) 2002-02-13 2003-08-20 Giovanni Scaramuzzino Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases
ATE448784T1 (de) 2002-02-14 2009-12-15 Pharmacia Corp Substituierte pyridinone als modulatoren für p38 map kinase
DE60316780T2 (de) 2002-02-21 2008-07-24 Eli Lilly And Co., Indianapolis Modulatoren von peroxisome proliferator-aktivierten rezeptoren
WO2003072757A2 (en) 2002-02-28 2003-09-04 Biota, Inc. Nucleotide mimics and their prodrugs
US7622592B2 (en) 2002-11-01 2009-11-24 Merck & Co., Inc. Carbonylamino-benzimidazole derivatives as androgen receptor modulators
US7189716B2 (en) 2003-01-03 2007-03-13 Bristol-Myers Squibb Company Tyrosine kinase inhibitors
KR101076018B1 (ko) 2003-01-08 2011-10-21 유니버시티 오브 워싱톤 항균제
US7122557B2 (en) 2003-03-18 2006-10-17 Bristol-Myers Squibb Company Sulfonyl-amidino-containing and tetrahydropyrimidino-containing compounds as factor Xa inhibitors
AU2004227362B2 (en) 2003-04-01 2008-06-26 Activx Biosciences, Inc. Acyl- phosphate and phosphonate probes and methods of their synthesis and use in proteomic analysis
EP1613261A4 (en) 2003-04-09 2011-01-26 Novo Nordisk As INTRA-CELLULAR FORMATION OF PEPTIDE CONJUGATES
US20040229839A1 (en) 2003-05-14 2004-11-18 Biocryst Pharmaceuticals, Inc. Substituted nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases
US7652044B2 (en) 2003-06-03 2010-01-26 Novartis A.G. P-38 inhibitors
GB0315111D0 (en) 2003-06-27 2003-07-30 Cancer Rec Tech Ltd Substituted 5-membered ring compounds and their use
WO2005000309A2 (en) 2003-06-27 2005-01-06 Ionix Pharmaceuticals Limited Chemical compounds
EP1673357A2 (en) 2003-08-08 2006-06-28 Vertex Pharmaceuticals Incorporated Heteroarylaminosulfonylphenyl derivatives for use as sodium or calcium channel blockers in the treatment of pain
EP1664072A1 (en) 2003-08-21 2006-06-07 Griffith University Novel sulfenamides
EP1664071A1 (en) 2003-08-21 2006-06-07 Griffith University Novel sulfenamide oxides
NZ546055A (en) 2003-08-27 2010-05-28 Biota Scient Management Novel tricyclic nucleosides or nucleotides as therapeutic agents
WO2005033079A1 (ja) 2003-09-30 2005-04-14 Eisai Co., Ltd. ヘテロ環化合物を含有する新規な抗真菌剤
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
JP4526801B2 (ja) 2003-11-13 2010-08-18 新日鐵化学株式会社 複素環化合物の製造方法
EP1532980A1 (en) 2003-11-24 2005-05-25 Novo Nordisk A/S N-heteroaryl indole carboxamides and analogues thereof, for use as glucokinase activators in the treatment of diabetes
EP1689407A1 (en) 2003-11-25 2006-08-16 Pfizer Products Inc. Method of treatment of atherosclerosis
AU2005266090A1 (en) 2004-07-23 2006-02-02 Pfizer Inc. Pyridine derivatives
CA2577169A1 (en) 2004-08-16 2006-02-23 The University Of Queensland Metabolism-modulating agents and uses therefor
KR20070057914A (ko) 2004-09-02 2007-06-07 버텍스 파마슈티칼스 인코포레이티드 이온 채널 조절인자로서 유용한 퀴나졸린
CA2600886A1 (en) 2005-03-08 2006-09-14 Biota Scientific Management Pty Ltd. Bicyclic nucleosides and nucleotides as therapeutic agents
WO2006113615A2 (en) 2005-04-15 2006-10-26 Sloan-Kettering Institute For Cancer Research Anti-microbial agents and uses thereof
JP2008543742A (ja) 2005-05-09 2008-12-04 バーテックス ファーマシューティカルズ インコーポレイテッド ビアリール尿素およびそのアナログの調製プロセス
WO2006124780A2 (en) 2005-05-12 2006-11-23 Kalypsys, Inc. Ih-benzo [d] imidazole compounds as inhibitors of b-raf kinase
GB0510141D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B3
EP1891039A1 (en) 2005-05-20 2008-02-27 Vertex Pharmaceuticals Incorporated Quinoline derivatives useful as modulators of ion channels
JP5388574B2 (ja) 2005-05-31 2014-01-15 バーテックス ファーマシューティカルズ インコーポレイテッド イオンチャネルのモジュレーターとして有用なヘテロ環式類
JP2007056213A (ja) 2005-08-26 2007-03-08 Fujifilm Corp 焼結含油軸受油用組成物、並びにそれを用いた軸受け装置及び摺動部材
ES2340531T3 (es) 2005-10-21 2010-06-04 Glaxo Group Limited Compuestos triciclos peri-condensados utiles como agentes antibacterianos.
WO2007052843A1 (ja) 2005-11-04 2007-05-10 Takeda Pharmaceutical Company Limited 複素環アミド化合物およびその用途
WO2007081966A2 (en) 2006-01-09 2007-07-19 University Of Southern California Small molecules for treating cancer and abnormal cell proliferation disorders
UY30118A1 (es) 2006-01-31 2007-06-29 Tanabe Seiyaku Co Compueto amina trisustituido
US20090264342A1 (en) 2006-02-13 2009-10-22 Trustees Of Boston University Compositions and methods for antibiotic potentiation and drug discovery
AR059826A1 (es) 2006-03-13 2008-04-30 Univ California Inhibidores de urea conformacionalmente restringidos de epoxido hidrolasa soluble
US7480400B2 (en) 2006-03-16 2009-01-20 Siemens Medical Solutions Usa, Inc. Detection of fiber pathways
EP2004596A2 (en) 2006-04-11 2008-12-24 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of voltage-gated sodium channels
CA2691214A1 (en) 2006-06-09 2007-12-21 Kemia, Inc. Therapy using cytokine inhibitors
EP2035395A2 (en) 2006-06-27 2009-03-18 Glenmark Pharmaceuticals S.A. Novel processes for the preparation of dpp iv inhibitors
US7842672B2 (en) 2006-07-07 2010-11-30 Gilead Sciences, Inc. Phosphonate inhibitors of HCV
PE20080948A1 (es) 2006-07-25 2008-09-10 Irm Llc Derivados de imidazol como moduladores de la senda de hedgehog
EP1882475A1 (en) 2006-07-26 2008-01-30 Novartis AG Method of treating disorders mediated by the fibroblast growth factor receptor
EA201501088A1 (ru) 2006-08-08 2017-01-30 Миллениум Фармасьютикалз, Инк. Гетероарильные соединения, применяемые в качестве ингибиторов e1 активирующих ферментов
JP5244596B2 (ja) 2006-08-09 2013-07-24 株式会社アイエスティー タンパク質の検出方法及びそれに用いる蛍光色素
JP2010502741A (ja) 2006-09-11 2010-01-28 キュリス，インコーポレイテッド Ｐｔｋインヒビターとしての亜鉛結合部分を含む置換２−インドリノン
AU2007296743B2 (en) 2006-09-11 2012-02-16 Curis, Inc. Tyrosine kinase inhibitors containing a zinc binding moiety
WO2008060789A2 (en) 2006-10-12 2008-05-22 Xenon Pharmaceuticals Inc. Use of spiro-oxindole compounds as therapeutic agents
JP2010510974A (ja) 2006-11-27 2010-04-08 ノバルティス アーゲー 置換ジヒドロイミダゾールおよび腫瘍の処置におけるその使用
KR101472765B1 (ko) 2006-12-08 2014-12-15 밀레니엄 파머슈티컬스 인코퍼레이티드 경구용 Ｘａ 인자 억제제를 포함하는 단위 용량 제형 및 경구용 Ｘａ 인자 억제제를 사용하는 혈전증의 치료 방법
US8236950B2 (en) 2006-12-20 2012-08-07 Abbott Laboratories Anti-viral compounds
FR2911138B1 (fr) 2007-01-05 2009-02-20 Sanofi Aventis Sa Nouveaux derives de n, n'-2,4-dianilinopyrimidines, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
FR2911140B1 (fr) 2007-01-05 2009-02-20 Sanofi Aventis Sa Nouveaux derives de 2-anilino 4-heteroaryle pyrimides, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
FR2911139A1 (fr) 2007-01-05 2008-07-11 Sanofi Aventis Sa Nouveaux derives de phenyl-(4-phenyl-pyrimidin-2-yl)amines, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
WO2008094507A2 (en) 2007-01-26 2008-08-07 Cellicon Biotechnologies, Inc. Novel fusion compounds
CN101674833A (zh) 2007-03-20 2010-03-17 柯瑞斯公司 含有锌结合半族的Raf激酶抑制剂
WO2008115262A2 (en) 2007-03-20 2008-09-25 Curis, Inc. Hsp90 inhibitors containing a zinc binding moiety
CA2684105C (en) 2007-05-03 2011-09-06 Pfizer Limited Pyridine derivatives
AU2008266856A1 (en) 2007-06-18 2008-12-24 University Of Louisville Research Foundation, Inc. Family of PFKFB3 inhibitors with anti-neoplastic activities
WO2009000413A1 (en) 2007-06-26 2008-12-31 Sanofi-Aventis A regioselective copper catalyzed synthesis of benzimidazoles and azabenzimidazoles
HRP20151052T1 (xx) 2007-07-19 2015-11-06 H. Lundbeck A/S Peteroäślani heterocikliäśki amidi i srodne tvari
JP4834699B2 (ja) 2007-07-30 2011-12-14 田辺三菱製薬株式会社 医薬組成物
JP4846769B2 (ja) 2007-07-30 2011-12-28 田辺三菱製薬株式会社 医薬組成物
FR2919869B1 (fr) 2007-08-09 2009-09-25 Sanofi Aventis Sa Nouveaux derives de n, n'-2,4-dianilinopyrimidines, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
WO2009036066A1 (en) 2007-09-10 2009-03-19 Curis, Inc. Vegfr inhibitors containing a zinc binding moiety
TW200920357A (en) 2007-09-10 2009-05-16 Curis Inc HSP90 inhibitors containing a zinc binding moiety
WO2009036051A1 (en) 2007-09-10 2009-03-19 Curis, Inc. Bcl-2 inhibitors containing a zinc binding moiety
US8367702B2 (en) 2007-09-26 2013-02-05 Astellas Pharma Inc. Quinolone derivative
JP5580201B2 (ja) 2007-10-08 2014-08-27 アドビヌス・セラピューティクス・プライベート・リミテッド グルコキナーゼアクチベータとしてのアセトアミド誘導体、その製法及び医薬応用
KR20100075631A (ko) 2007-10-11 2010-07-02 버텍스 파마슈티칼스 인코포레이티드 전압­개폐 나트륨 채널의 억제제로서 유용한 아릴 아미드
WO2009049181A1 (en) 2007-10-11 2009-04-16 Vertex Pharmaceuticals Incorporated Amides useful as inhibitors of voltage-gated sodium channels
AU2008310660A1 (en) 2007-10-11 2009-04-16 Vertex Pharmaceuticals Incorporated Heteroaryl amides useful as inhibitors of voltage-gated sodium channels
WO2009069132A2 (en) 2007-11-29 2009-06-04 Ramot At Tel Aviv University Ltd. Novel reverse transcriptase inhibitors
JP5637859B2 (ja) 2007-12-13 2014-12-10 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ 嚢胞性線維症膜コンダクタンスレギュレーターのモジュレーター
WO2009086303A2 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
US20110046199A1 (en) 2008-01-17 2011-02-24 Purdue Research Foundation Small molecule inhibitors of hiv proteases
US20120108630A1 (en) 2008-02-12 2012-05-03 The Board Of Trustees Of The Leland Stanford Junior University Hedgehog Pathway Antagonists and Methods of Use
WO2009114470A2 (en) 2008-03-10 2009-09-17 Curis, Inc. Tetrahydroindole and tetrahdyroindazole as hsp90 inhibitors containing a zinc binding moiety
JP5219583B2 (ja) 2008-03-31 2013-06-26 住友化学株式会社 組成物、光学フィルムとその製造方法、光学部材及び表示装置
CA2721060A1 (en) 2008-04-09 2009-10-15 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
US9029408B2 (en) 2008-06-16 2015-05-12 Gtx, Inc. Compounds for treatment of cancer
MX2010014066A (es) 2008-06-16 2011-06-01 Univ Tennessee Res Foundation Compuestos para el tratamiento del cancer.
CA2729128C (en) 2008-07-03 2016-05-31 Sirtris Pharmaceuticals, Inc. Benzimidazoles and related analogs as sirtuin modulators
JP5443720B2 (ja) 2008-09-05 2014-03-19 住友化学株式会社 組成物、光学フィルム及びその製造方法、光学部材ならびに表示装置
US8541569B2 (en) 2008-09-06 2013-09-24 Chemgenes Corporation Phosphoramidites for synthetic RNA in the reverse direction, efficient RNA synthesis and convenient introduction of 3'-end ligands, chromophores and modifications of synthetic RNA
US8309707B2 (en) 2008-09-06 2012-11-13 Chemgenes Corporation RNA synthesis-phosphoramidites for synthetic RNA in the reverse direction, and application in convenient introduction of ligands, chromophores and modifications of synthetic RNA at the 3′-end
US8354444B2 (en) 2008-09-18 2013-01-15 Hoffmann-La Roche Inc. Substituted pyrrolidine-2-carboxamides
MY160424A (en) 2008-09-18 2017-03-15 Hoffmann La Roche Substituted pyrrolidine-2-carboxyamides.
MX2011003373A (es) 2008-09-29 2011-06-09 Sirtris Pharmaceuticals Inc Quinazolinona, quinolona y analogos relacionados como moduladores de sirtuina.
WO2010048149A2 (en) 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
EP2184273A1 (de) 2008-11-05 2010-05-12 Bayer CropScience AG Halogen-substituierte Verbindungen als Pestizide
EP2384328B1 (en) 2008-11-27 2013-02-13 Boehringer Ingelheim International GmbH 6,7,8,9-tetrahydro-5h-1,4,7,10a-tetraaza-cyclohept[f]indene derivatives, pharmaceutical compositions containing these compounds, their use and process for preparing them
GB0821913D0 (en) 2008-12-02 2009-01-07 Price & Co Antibacterial compounds
EP2376473A4 (en) 2008-12-10 2012-05-02 Merck Canada Inc 3,4-SUBSTITUTED PIPERIDINE DERIVATIVES AS RENIN INHIBITORS
US20120040916A1 (en) 2008-12-22 2012-02-16 Massachusetts Institute Of Technology Molecular inhibitors of the wnt/beta-catenin pathway
MX2011006843A (es) 2008-12-23 2011-08-04 Hoffmann La Roche Dihidropiridona-amidas como moduladores de p2x7.
MX2011006904A (es) 2008-12-26 2011-07-20 Dainippon Sumitomo Pharma Co Compuesto heterociclico biciclico novedoso.
KR20100087540A (ko) 2009-01-28 2010-08-05 삼성전자주식회사 잉크젯 기록용 잉크 조성물
EP2408449A4 (en) 2009-03-18 2012-08-08 Univ Leland Stanford Junior METHOD AND COMPOSITIONS FOR TREATING FLAVIVIRIDAE VIRUS INFECTIONS
MY159575A (en) 2009-04-02 2017-01-13 Merck Serono Sa Dihydroorotate dehydrogenase inhibitors
US8557400B2 (en) 2009-04-28 2013-10-15 Universal Display Corporation Iridium complex with methyl-D3 substitution
CA2760946C (en) 2009-05-07 2019-06-25 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for studying, imaging, and treating pain
JP2012528174A (ja) 2009-05-27 2012-11-12 アボット・ラボラトリーズ キナーゼ活性のピリミジン阻害剤
JP2012528175A (ja) 2009-05-27 2012-11-12 アボット・ラボラトリーズ キナーゼ活性のピリミジン阻害剤
CN105254557A (zh) 2009-05-29 2016-01-20 拉夸里亚创药株式会社 作为钙或钠通道阻滞剂的芳基取代羧酰胺衍生物
TW201103904A (en) 2009-06-11 2011-02-01 Hoffmann La Roche Janus kinase inhibitor compounds and methods
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
WO2011005860A2 (en) 2009-07-07 2011-01-13 Alnylam Pharmaceuticals, Inc. 5' phosphate mimics
WO2011026240A1 (en) 2009-09-04 2011-03-10 Zalicus Pharmaceuticals Ltd. Oxopiperazine derivatives for the treatment of pain and epilepsy
WO2011032169A2 (en) 2009-09-14 2011-03-17 Phusis Therapeutics Inc. Pharmaceutical compositions and formulations including inhibitors of the pleckstrin homology domain and methods for using same
US20110124597A1 (en) 2009-09-25 2011-05-26 Anacor Pharmaceuticals, Inc. Boron containing small molecules
WO2011047320A2 (en) 2009-10-16 2011-04-21 Rib-X Pharmaceuticals, Inc. Antimicrobial compounds and methods of making and using the same
US11084811B2 (en) 2010-03-01 2021-08-10 Oncternal Therapeutics, Inc. Compounds for treatment of cancer
JP5879273B2 (ja) 2010-03-01 2016-03-08 ジーティーエックス・インコーポレイテッド 癌を処置するための化合物
US8598164B2 (en) 2010-05-06 2013-12-03 Vertex Pharmaceuticals Incorporated Heterocyclic chromene-spirocyclic piperidine amides as modulators of ion channels
AU2011251622A1 (en) 2010-05-10 2012-12-20 Radikal Therapeutics Inc. Lipoic acid and nitroxide derivatives and uses thereof
WO2011151619A1 (en) 2010-06-01 2011-12-08 Summit Corporation Plc Compounds for the treatment of clostridium difficile associated disease
US20120010235A1 (en) 2010-07-12 2012-01-12 Xin-Jie Chu N-substituted pyrrolidines
WO2012016133A2 (en) 2010-07-29 2012-02-02 President And Fellows Of Harvard College Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers
US9290485B2 (en) 2010-08-04 2016-03-22 Novartis Ag N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides
WO2012020725A1 (ja) 2010-08-10 2012-02-16 塩野義製薬株式会社 Ｎｐｙ ｙ５受容体拮抗作用を有するヘテロ環誘導体
RU2013120966A (ru) 2010-10-08 2014-11-20 Эббви Инк. ФУРО[3,2-d]ПИРИМИДИНОВЫЕ СОЕДИНЕНИЯ
GB201017315D0 (en) 2010-10-13 2010-11-24 Antoxis Ltd Compound
US9394290B2 (en) 2010-10-21 2016-07-19 Universitaet Des Saarlandes Campus Saarbruecken Selective CYP11B1 inhibitors for the treatment of cortisol dependent diseases
FI20106119A0 (fi) 2010-10-27 2010-10-27 Sirtuin Valley Oy Energia-aineenvaihduntaan vaikuttava koostumus
GB201020076D0 (en) 2010-11-26 2011-01-12 Liverpool School Tropical Medicine Antimalarial compounds
DK2646436T3 (en) 2010-11-29 2015-06-29 Pfizer monobactams
WO2012080729A2 (en) 2010-12-14 2012-06-21 Electrophoretics Limited CASEIN KINASE 1δ (CK1δ) INHIBITORS
TWI574687B (zh) 2011-01-03 2017-03-21 古利斯股份有限公司 具有鋅結合部份之刺蝟拮抗劑
WO2012097330A2 (en) 2011-01-14 2012-07-19 University Of Washington Compositions and methods for treating degenerative muscle conditions
EP2670704B1 (en) 2011-02-02 2018-12-12 Bio-Rad Laboratories, Inc. Apatite surface neutralization with alkali solutions
WO2012106534A2 (en) 2011-02-02 2012-08-09 The Regents Of The University Of California Hiv integrase inhibitors
KR101923367B1 (ko) 2011-02-02 2018-12-04 버텍스 파마슈티칼스 인코포레이티드 이온 채널의 조절제로서의 피롤로피라진―스피로사이클릭 피페리딘 아미드
JP2012167027A (ja) 2011-02-10 2012-09-06 Shionogi & Co Ltd Ｎｐｙｙ５受容体拮抗作用を有する縮合ヘテロ環誘導体
MX2013009393A (es) 2011-02-18 2013-08-29 Vertex Pharma Piperidinamidas cromano-espirociclicas como moduladores de canales de iones.
CA2828456C (en) 2011-03-03 2021-05-04 Zalicus Pharmaceuticals Ltd. N-benzl-amino-carboxamide inhibitors of the sodium channel
CN103517910B (zh) 2011-03-14 2016-12-14 沃泰克斯药物股份有限公司 作为离子通道调节剂的吗啉-螺环哌啶酰胺
WO2012125797A1 (en) 2011-03-15 2012-09-20 Abbott Laboratories Nuclear hormone receptor modulators
US9464065B2 (en) 2011-03-24 2016-10-11 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
JP5866100B2 (ja) 2011-04-13 2016-02-17 住友化学株式会社 レジスト組成物及びレジストパターンの製造方法
WO2012155066A2 (en) 2011-05-11 2012-11-15 Shaomeng Wang Spiro-oxindole mdm2 antagonists
JP6007417B2 (ja) 2011-05-31 2016-10-12 レセプトス エルエルシー 新規ｇｌｐ−１受容体安定剤および調節剤
WO2012170371A1 (en) 2011-06-10 2012-12-13 N30 Pharmaceuticals, Llc Compounds as s-nitrosoglutathione reductase inhibitors
US8822469B2 (en) 2011-06-22 2014-09-02 Vertex Pharmaceuticals Incorporated Pyrrolo[2,3-B]pyrazines useful as inhibitors of ATR kinase
WO2013005057A1 (en) 2011-07-07 2013-01-10 Centro Nacional De Investigaciones Oncológicas (Cnio) New compounds
GB201111705D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Compounds and their use
WO2013022740A2 (en) 2011-08-05 2013-02-14 Corning Incorporated Gpr35 ligands and the uses thereof
PT2755965T (pt) 2011-09-12 2017-11-02 Merck Patent Gmbh Novas imidazol aminas como moduladores da atividade quinase
US20140241990A1 (en) 2011-09-30 2014-08-28 Tufts University Methods of using adenosine a1 receptor activation for treating depression
CA2850925C (en) 2011-10-26 2017-01-10 Pfizer Limited (4-phenylimidazol-2-yl) ethylamine derivatives useful as sodium channel modulators
US9012443B2 (en) 2011-12-07 2015-04-21 Amgen Inc. Bicyclic aryl and heteroaryl sodium channel inhibitors
CN103159738B (zh) 2011-12-19 2016-09-07 上海泓博智源医药股份有限公司 炔基桥连的杂芳香化合物及其应用
NZ627259A (en) 2012-01-16 2016-12-23 Vertex Pharma Pyran-spirocyclic piperidine amides as modulators of ion channels
FR2985916B1 (fr) 2012-01-25 2015-12-04 Univ Bordeaux Segalen Decontamination par hydrogels d'echantillons aqueux contenant des nanoparticules
JP6002785B2 (ja) 2012-02-03 2016-10-05 ファイザー・インク ナトリウムチャネルモジュレーターとしてのベンゾイミダゾールおよびイミダゾピリジン誘導体
CN104395335A (zh) 2012-02-08 2015-03-04 努艾利克斯德国股份有限公司 用于抗体和Fc-融合蛋白亲和色谱IV纯化的配体
CN104136576B (zh) 2012-02-22 2020-10-16 默克专利股份有限公司 液晶介质
WO2013131018A1 (en) 2012-03-02 2013-09-06 Zalicus Pharmaceuticals Ltd. Biaryl inhibitors of the sodium channel
DK2822953T5 (en) 2012-03-06 2017-09-11 Pfizer Macrocyclic derivatives for the treatment of proliferative diseases
JP5798066B2 (ja) 2012-03-08 2015-10-21 富士フイルム株式会社 化合物、液晶組成物、高分子材料およびフィルム
WO2013134518A1 (en) 2012-03-09 2013-09-12 Amgen Inc. Sulfamide sodium channel inhibitors
JP5804991B2 (ja) 2012-03-19 2015-11-04 富士フイルム株式会社 光反射フィルム、自動車用フロントガラス、建材用ガラス
WO2013151975A1 (en) 2012-04-02 2013-10-10 Northeastern University Compositions and methods for the inhibition of methyltransferases
BR112014029530A2 (pt) 2012-05-30 2017-06-27 Hoffmann La Roche compostos, composição farmacêutica e uso de um composto
JP5867298B2 (ja) 2012-06-06 2016-02-24 Jsr株式会社 フォトレジスト組成物及びレジストパターン形成方法
WO2013188881A1 (en) 2012-06-15 2013-12-19 President And Fellows Of Harvard College Compounds, compositions and methods for treating or preventing neurodegenerative disorders
US20140005181A1 (en) 2012-06-21 2014-01-02 Sanford-Burnham Medical Research Institute Small molecule antagonists of the apelin receptor for the treatment of disease
WO2014003153A1 (ja) 2012-06-28 2014-01-03 協和発酵キリン株式会社 置換アミド化合物
WO2014005125A2 (en) 2012-06-29 2014-01-03 Biotium, Inc. Fluorescent compounds and uses thereof
US9040498B2 (en) 2012-07-06 2015-05-26 Research Foundation Of The City University Of New York 1,2,3-Triazolyl purine derivatives
AR091786A1 (es) 2012-07-17 2015-02-25 Boehringer Ingelheim Int Inhibidores de la produccion de leucotrienos
CN104640843A (zh) 2012-07-19 2015-05-20 大日本住友制药株式会社 1-(环烷基羰基)脯氨酸衍生物
JP6324380B2 (ja) 2012-07-27 2018-05-16 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． Ｓ１ｐ調節剤および／またはａｔｘ調節剤である化合物
WO2014015523A1 (en) 2012-07-27 2014-01-30 Hutchison Medipharma Limited Novel heteroaryl and heterocycle compounds, compositions and methods
WO2014020152A1 (en) 2012-08-02 2014-02-06 Graffinity Pharmaceuticals Gmbh Ligands for apheresis and immunoabsorption
EP2892899B1 (en) 2012-09-06 2018-03-21 Bristol-Myers Squibb Company Imidazopyridazine jak3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases
KR101992929B1 (ko) 2012-09-20 2019-06-25 템플 유니버시티-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 치환된 알킬 디아릴 유도체, 제조방법 및 용도
UA110688C2 (uk) 2012-09-21 2016-01-25 Пфайзер Інк. Біциклічні піридинони
FR2997851B1 (fr) 2012-11-09 2014-11-28 Oreal Composition comprenant un derive dicarbonyle et procede de lissage des cheveux a partir de cette composition
CA2890897A1 (en) 2012-11-14 2014-05-22 The Board Of Regents Of The University Of Texas System Inhibition of hif-2.alpha. heterodimerization with hif 1.beta. (arnt)
BR112015011147A8 (pt) 2012-11-16 2019-10-01 Merck Sharp & Dohme composto, composição farmacêutica, e, uso do referido composto
EP2928877B1 (en) 2012-12-06 2020-01-22 Merck Sharp & Dohme Corp. Disulfide masked prodrug compositions and methods
HK1211287A1 (en) 2013-01-08 2016-05-20 Savira Pharmaceuticals Gmbh Pyridone derivatives and their use in the treatment, amelioration or prevention of a viral disease
US20140200215A1 (en) 2013-01-15 2014-07-17 Intermune, Inc. Lysophosphatidic acid receptor antagonists
SMT201700317T1 (it) 2013-01-29 2017-09-07 Redx Pharma Plc Derivati piridinici in qualità di inibitori rock teneri
CA2898653C (en) 2013-01-31 2021-09-28 Vertex Pharmaceuticals Incorporated Amides as modulators of sodium channels
RU2683788C2 (ru) 2013-01-31 2019-04-02 Вертекс Фармасьютикалз Инкорпорейтед Амиды хинолина и хиназолина, полезные в качестве модуляторов натриевых каналов
RS56015B1 (sr) 2013-01-31 2017-09-29 Vertex Pharma Piridon amidi kao modulatori natrijumovih kanala
TWI606048B (zh) 2013-01-31 2017-11-21 帝人製藥股份有限公司 唑苯衍生物
US20140357636A1 (en) 2013-02-21 2014-12-04 Wayne Rothbaum Treatment of Skeletal-Related Disorders
WO2014134127A1 (en) 2013-02-26 2014-09-04 Northeastern University Cannabinergic nitrate esters and related analogs
WO2014151958A1 (en) 2013-03-14 2014-09-25 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
WO2014179785A1 (en) 2013-05-03 2014-11-06 Inscent, Inc. Improved honeybee repellents and uses thereof
JP2014232188A (ja) 2013-05-29 2014-12-11 コニカミノルタ株式会社 セルロースアシレートフィルム、円偏光板及び画像表示装置
US9776995B2 (en) 2013-06-12 2017-10-03 Amgen Inc. Bicyclic sulfonamide compounds as sodium channel inhibitors
TWI637949B (zh) 2013-06-14 2018-10-11 塩野義製藥股份有限公司 胺基三衍生物及含有其等之醫藥組合物
TW201534597A (zh) 2013-06-20 2015-09-16 Ab Science 作為選擇性蛋白質激酶抑制劑之苯并咪唑衍生物
WO2015003991A1 (en) 2013-07-12 2015-01-15 Syngenta Participations Ag Novel microbiocides
CN105793424B (zh) 2013-07-12 2021-02-19 亥姆霍兹感染研究中心有限公司 孢囊菌酰胺
WO2015003723A1 (en) 2013-07-12 2015-01-15 Københavns Universitet Substituted 4-proline derivatives as iglur antagonists
UA119147C2 (uk) 2013-07-19 2019-05-10 Вертекс Фармасьютікалз Інкорпорейтед Сульфонаміди як модулятори натрієвих каналів
WO2015011284A2 (en) 2013-07-25 2015-01-29 Fondazione Telethon Inhibitors of fapp2 and uses thereof
WO2015035051A1 (en) 2013-09-04 2015-03-12 Board Of Regents Of The University Of Texas System Methods and compositions for selective and targeted cancer therapy
LT3043803T (lt) 2013-09-11 2022-08-10 Emory University Nukleotidų ir nukleozidų kompozicijos ir jų panaudojimas
KR101628288B1 (ko) 2013-09-30 2016-06-08 주식회사 엘지화학 음성 광학 분산도를 갖는 광학 소자 제조용 조성물 및 이로부터 제조된 광학 이방체
JP2016534984A (ja) 2013-10-01 2016-11-10 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ アフィニティークロマトグラフィーのためおよび治療薬の半減期の延長のための化合物
EP3052479A4 (en) 2013-10-02 2017-10-25 Moderna Therapeutics, Inc. Polynucleotide molecules and uses thereof
US9700881B2 (en) 2013-10-09 2017-07-11 Emory University Heterocyclic coupling catalysts and methods related thereto
MX2016007259A (es) 2013-12-03 2016-08-04 Du Pont Pirrolidinonas como herbicidas.
WO2015085238A1 (en) 2013-12-05 2015-06-11 The Regents Of The University Of California, A California Corporation Inhibitors of lpxc
CA2931550C (en) 2013-12-13 2023-09-26 Vertex Pharmaceuticals Incorporated Prodrugs of pyridone amides useful as modulators of sodium channels
EP3053585A1 (en) 2013-12-13 2016-08-10 Moderna Therapeutics, Inc. Alternative nucleic acid molecules and uses thereof
KR20150070027A (ko) 2013-12-16 2015-06-24 메르크 파텐트 게엠베하 액정 매질
US9611252B2 (en) 2013-12-30 2017-04-04 Lifesci Pharmaceuticals, Inc. Therapeutic inhibitory compounds
CA2935683A1 (en) 2013-12-30 2015-07-09 Lifesci Pharmaceuticals, Inc. Therapeutic inhibitory compounds
WO2015157559A2 (en) 2014-04-09 2015-10-15 Siteone Therapeutics, Inc. 10',11'-modified saxitoxins for the treatment of pain
WO2015162244A1 (en) 2014-04-25 2015-10-29 Basf Se N-acylamidine compounds
JP6295992B2 (ja) 2014-05-09 2018-03-20 信越化学工業株式会社 単量体の製造方法
US9701627B2 (en) 2014-06-16 2017-07-11 University Of Maryland, Baltimore LRRK2 GTP binding inhibitors for treatment of Parkinson's disease and neuroinflammatory disorders
WO2015196128A2 (en) 2014-06-19 2015-12-23 Moderna Therapeutics, Inc. Alternative nucleic acid molecules and uses thereof
WO2015196118A1 (en) 2014-06-19 2015-12-23 Moderna Therapeutics, Inc. Alternative nucleic acid molecules and uses thereof
US20170175129A1 (en) 2014-06-19 2017-06-22 Moderna Therapeutics, Inc. Alternative nucleic acid molecules and uses thereof
EA201692301A1 (ru) 2014-07-01 2017-06-30 Ремпекс Фармасьютикалз, Инк. Производные бороновой кислоты и их терапевтическое применение
WO2016007837A1 (en) 2014-07-11 2016-01-14 Spero Therapeutics, Inc. Carbonyl linked bicyclic heteroaryl antibiotic tolerance inhibitors
AU2015289643B2 (en) 2014-07-16 2020-10-22 Attune Pharmaceuticals, Inc. Therapeutic inhibitory compounds
EP2977374A1 (en) 2014-07-21 2016-01-27 Université de Strasbourg Molecules presenting dual emission properties
EP2985334B1 (en) 2014-08-15 2018-06-20 Merck Patent GmbH Liquid-crystalline medium
US10913736B2 (en) 2014-08-22 2021-02-09 University Of Washington Specific inhibitors of methionyl-tRNA synthetase
BR112017004612A2 (pt) 2014-09-10 2018-01-30 Epizyme, Inc. compostos, composição farmacêutica, usos de um composto, e kit
WO2016040449A1 (en) 2014-09-10 2016-03-17 Raze Therapeutics, Inc. 3-phosphoglycerate dehydrogenase inhibitors and uses thereof
JP2016079098A (ja) 2014-10-10 2016-05-16 塩野義製薬株式会社 セフェム化合物
JP2017538676A (ja) 2014-11-05 2017-12-28 ザ ユニバーシティ オブ カンザス ミトコンドリア透過性遷移孔（ｍｔＰＴＰ）の小分子阻害剤
EP3229611B1 (en) 2014-12-10 2025-03-26 Mars, Incorporated Compounds that modulate fatty acid receptor activity and pet food products containing the same
FR3030242B1 (fr) 2014-12-18 2018-01-26 L'oreal Emulsion contenant un tensioactif gemine ayant deux groupements amide gras et un filtre uv organique hydrosoluble
CN105985330A (zh) 2015-02-04 2016-10-05 苏州旺山旺水生物医药有限公司 一类杂环化合物、其制备方法和用途
JP6394430B2 (ja) 2015-02-13 2018-09-26 信越化学工業株式会社 化合物、高分子化合物、レジスト材料及びパターン形成方法
EA032928B1 (ru) 2015-03-02 2019-08-30 Эмджен Инк. Бициклические кетосульфонамидные соединения
WO2016145142A1 (en) 2015-03-10 2016-09-15 Emory University Nucleotide and nucleoside therapeutics compositions and uses related thereto
EP3085360A1 (en) 2015-04-20 2016-10-26 Universite De Bordeaux Lipid based nanocarrier compositions loaded with metal nanoparticles and therapeutic agent
WO2016172631A2 (en) 2015-04-24 2016-10-27 President And Fellows Of Harvard College Substrate selective inhibitors of insulin-degrading enzyme (ide) and uses thereof
CN107849024A (zh) 2015-05-15 2018-03-27 吉利德科学公司 具有作为吲哚胺2,3‑二加氧酶抑制剂活性的苯并咪唑和咪唑并吡啶亚氨代甲酰胺化合物
CN107709310B (zh) 2015-06-02 2021-09-24 Fmc公司 取代的环酰胺及其作为除草剂的用途
WO2016198908A1 (en) 2015-06-09 2016-12-15 Abbvie Inc. Ror nuclear receptor modulators
EP3319943B1 (de) 2015-07-06 2019-06-26 Bayer CropScience Aktiengesellschaft Stickstoffhaltige heterocyclen als schädlingsbekämpfungsmittel
EP3319944A4 (en) 2015-07-10 2019-04-24 Arvinas, Inc. MDM2-BASED MODULATORS OF PROTEOLYSIS AND RELATED USE METHODS
CN106518766A (zh) 2015-09-11 2017-03-22 中国人民解放军军事医学科学院毒物药物研究所 新型二芳基脲类化合物,其制备方法及其医药用途
CN106518767A (zh) 2015-09-11 2017-03-22 中国人民解放军军事医学科学院毒物药物研究所 取代苯并吡唑二芳基脲类化合物,其制备方法及其医药用途
WO2017051319A1 (en) 2015-09-21 2017-03-30 Glenmark Pharmaceuticals S.A. Aryl and heteroaryl ether compounds as ror gamma modulators
ES2895155T3 (es) 2015-09-30 2022-02-17 Siteone Therapeutics Inc Saxitoxinas modificadas en 11,13 para el tratamiento del dolor
WO2017059446A1 (en) 2015-10-01 2017-04-06 Memorial Sloan-Kettering Cancer Center Anthranilyl-adenosinemonosulfamate analogs and uses thereof
WO2017062751A1 (en) 2015-10-08 2017-04-13 The Regents Of The University Of California Compounds and methods for promoting stress resistance
WO2017066705A1 (en) 2015-10-14 2017-04-20 Aquinnah Pharmaceuticals, Inc. Compounds, compositions and methods of use against stress granules
WO2017066791A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Sugar substituted mrna cap analogs
WO2017066782A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Hydrophobic mrna cap analogs
SI3362461T1 (sl) 2015-10-16 2022-05-31 Modernatx, Inc. Analogi kape MRNA z modificirano fosfatno povezavo
WO2017090743A1 (ja) 2015-11-27 2017-06-01 田辺三菱製薬株式会社 新規イミダゾール化合物およびメラノコルチン受容体作動薬としての用途
GB201522232D0 (en) 2015-12-16 2016-01-27 Liverpool School Tropical Medicine Combination product
KR102606339B1 (ko) 2016-03-02 2023-11-24 삼성전자주식회사 유기금속 화합물 및 이를 포함한 유기 발광 소자
PL3429591T3 (pl) 2016-03-16 2023-07-17 Kura Oncology, Inc. Podstawione pochodne tieno[2,3-d]pirymidyny jako inhibitory meniny-mll i metody ich zastosowania
GB201604638D0 (en) 2016-03-18 2016-05-04 Mission Therapeutics Ltd Novel compounds
ES2946970T3 (es) 2016-03-31 2023-07-28 Vertex Pharma Regulador de conductancia transmembrana de moduladores de fibrosis quística
CN105906591A (zh) 2016-04-22 2016-08-31 中国药科大学 2-氨基-γ-丁内酯类盐酸盐的合成
WO2017223260A1 (en) 2016-06-23 2017-12-28 Albert Einstein College Of Medicine, Inc. Pu.1 inhibitors
CN106220667B (zh) 2016-07-21 2018-10-30 北京航空航天大学 螺环有机硅化合物及其应用
WO2018045106A1 (en) 2016-08-30 2018-03-08 Ohio State Innovation Foundation Anti-fungal treatment
WO2018055235A1 (en) 2016-09-21 2018-03-29 University Of Helsinki Isoxazole-amides for treating cardiac diseases
WO2018064119A1 (en) 2016-09-28 2018-04-05 Blade Therapeutics, Inc. Calpain modulators and therapeutic uses thereof
CN109790468B (zh) 2016-09-28 2023-06-13 默克专利股份有限公司 可聚合的液晶材料及经聚合的液晶膜
US11179708B2 (en) 2016-10-04 2021-11-23 Massachusetts Institute Of Technology Compositions and methods for selective carbonylation of heterocyclic compounds
CN110099909B (zh) 2016-12-12 2021-11-19 杭州英创医药科技有限公司 作为Syk抑制剂和/或Syk-HDAC双重抑制剂的杂环化合物
EP3656382A1 (en) 2017-01-30 2020-05-27 Université de Liège Perk and ire-1a inhibitors against neurodevelopmental disorders
WO2018161033A1 (en) 2017-03-02 2018-09-07 Wright, Adrian Small molecule ire1-alpha inhibitors
CN108658974A (zh) 2017-03-28 2018-10-16 中国海洋大学 一种内酰胺类化合物及其制备方法和用途
CN108658972A (zh) 2017-03-28 2018-10-16 中国海洋大学 一种取代内酰胺类化合物及其制备方法和用途
CN110831945B (zh) 2017-03-29 2023-08-08 赛特温治疗公司 用于治疗疼痛的11,13-修饰的石房蛤毒素类化合物
US11279706B2 (en) 2017-03-29 2022-03-22 Siteone Therapeutics, Inc. 11,13-modified saxitoxins for the treatment of pain
US20200113901A1 (en) 2017-03-31 2020-04-16 Epizyme, Inc. Methods of using ehmt2 inhibitors
JP2020100564A (ja) 2017-04-03 2020-07-02 京都薬品工業株式会社 リードスルー誘導剤およびその医薬用途
WO2018191146A1 (en) 2017-04-10 2018-10-18 Navitor Pharmaceuticals, Inc. Heteroaryl rheb inhibitors and uses thereof
CN108689942B (zh) 2017-04-11 2023-06-09 广东东阳光药业有限公司 含氮双环化合物及其制备方法和用途
EP3612526A2 (en) 2017-04-20 2020-02-26 The Regents of the University of California K-ras modulators
CN110621316B (zh) 2017-04-21 2024-01-26 Epizyme股份有限公司 用ehmt2抑制剂进行的组合疗法
EP3625214B1 (en) 2017-05-16 2022-07-06 Vertex Pharmaceuticals Incorporated Deuterated pyridone amides and prodrugs thereof as modulators of sodium channels
CN107033149B (zh) 2017-06-12 2020-01-03 上海交通大学 一种dpp-4酶抑制剂及其制备和应用
US11718638B2 (en) 2017-06-21 2023-08-08 Wave Life Sciences Ltd. Compounds, compositions and methods for synthesis
CN109320509B (zh) 2017-07-31 2022-02-08 轩竹生物科技股份有限公司 Fxr受体激动剂
CN109384712B (zh) 2017-08-14 2021-05-07 北京宽厚医药科技有限公司 靶向nk1受体拮抗剂及其在化疗所致恶心、呕吐治疗中的应用
BR112020003116A2 (pt) 2017-08-17 2020-08-04 Ikena Oncology, Inc. inibidores de ahr e usos dos mesmos
US11795162B2 (en) 2017-08-18 2023-10-24 Saint Louis University Modulators of the estrogen-related receptor
CN109553608B (zh) 2017-09-26 2020-12-08 北京大学 一类五元六元杂环化合物及其制备方法和治疗肿瘤的用途
AU2018353139A1 (en) 2017-10-18 2020-06-04 Epizyme, Inc. Methods of using EHMT2 inhibitors in immunotherapies
JP2021500326A (ja) 2017-10-18 2021-01-07 エピザイム，インコーポレイティド 血液障害の予防又は処置にｅｈｍｔ２阻害剤を使用する方法
WO2019084271A1 (en) 2017-10-25 2019-05-02 Children's Medical Center Corporation PAPD5 INHIBITORS AND METHODS OF USE
EP3479843A1 (en) 2017-11-01 2019-05-08 GenKyoTex Suisse SA Use of nox inhibitors for treatment of cancer
TW201922690A (zh) 2017-11-10 2019-06-16 中央研究院 環－amp反應元素結合蛋白的抑制劑
IL274504B2 (en) 2017-11-15 2024-12-01 Epivario Inc Acss2 inhibitors and methods of use thereof
EP3502684A1 (en) 2017-12-22 2019-06-26 Universite De Bordeaux Method for metal ion detection in aqueous solutions using nucleolipid compounds
KR20190076339A (ko) 2017-12-22 2019-07-02 한미약품 주식회사 신규한 2,6-나프티리딘 2-옥시드 유도체 화합물 및 이의 용도
CN111315744B (zh) 2018-01-09 2023-07-14 四川科伦博泰生物医药股份有限公司 杂芳基并四氢吡啶类化合物、其制备方法、药物组合物及应用
CA3087830A1 (en) 2018-02-08 2019-08-15 Enyo Pharma Non-fused thiophene derivatives and their uses
US11529337B2 (en) 2018-02-12 2022-12-20 Vertex Pharmaceuticals Incorporated Method of treating pain
WO2019195439A1 (en) 2018-04-05 2019-10-10 St. Jude Medical, Cardiology Division, Inc. High density electrode mapping catheter
WO2019207081A1 (en) 2018-04-27 2019-10-31 Merck Patent Gmbh Polymerisable liquid crystal material and polymerised liquid crystal film
WO2019206925A1 (en) 2018-04-27 2019-10-31 Merck Patent Gmbh Polymerisable liquid crystal material and polymerised liquid crystal film
WO2019222414A1 (en) 2018-05-16 2019-11-21 Belite Bio, Llc Fatty acid analogues and methods of use
TWI812739B (zh) 2018-06-21 2023-08-21 景凱生物科技股份有限公司 Nadph氧化酶抑制劑、含其的醫藥組合物、及其應用
AU2019302534B2 (en) 2018-07-09 2024-10-03 Lieber Institute, Inc. Pyridazine compounds for inhibiting NaV1.8
CA3105657A1 (en) 2018-07-09 2020-01-16 Lieber Institute, Inc. Pyridine carboxamide compounds for inhibiting nav1.8
US20210347785A1 (en) 2018-08-01 2021-11-11 Shanghai Ennovabio Pharmaceuticals Co., Ltd. Preparation and application of aromatic compound having immunoregulatory function
US11945803B2 (en) 2018-08-07 2024-04-02 Tosk, Inc. Modulators of RAS GTPase
WO2020034062A1 (en) 2018-08-13 2020-02-20 Rhodia Operations Process for the reductive amination of a carbonyl compound
WO2020034058A1 (en) 2018-08-13 2020-02-20 Rhodia Operations PROCESS FOR REDUCTIVE AMINATION OF α,β-UNSATURATED CARBONYL COMPOUND
JP2021536458A (ja) 2018-09-04 2021-12-27 マジェンタ セラピューティクス インコーポレイテッドMagenta Therapeutics, Inc. アリール炭化水素レセプター・アンタゴニスト及び使用方法
MX2021003559A (es) 2018-09-28 2021-08-24 Acucela Inc Inhibidores de vap-1.
KR102092838B1 (ko) 2018-10-02 2020-03-24 성균관대학교산학협력단 신규 퓨란계 폴리카보네이트 및 이의 제조 방법
EP3860714B1 (en) 2018-10-03 2023-09-06 Siteone Therapeutics, Inc. 11,13-modified saxitoxins for the treatment of pain
TW202028183A (zh) 2018-10-10 2020-08-01 大陸商江蘇豪森藥業集團有限公司 含氮雜芳類衍生物調節劑、其製備方法和應用
EP3866798A4 (en) 2018-10-15 2022-07-13 Dana-Farber Cancer Institute, Inc. ENHANCED TRANSCRIPTIONAL ASSOCIATED DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND THEIR USES
US12344595B2 (en) 2018-11-02 2025-07-01 Merck Sharp & Dohme Llc 2-amino-n-phenyl-nicotinamides as NAV1.8 inhibitors
KR102151855B1 (ko) 2018-11-30 2020-09-03 롯데케미칼 주식회사 공액 디엔계 및 방향족 비닐계 공중합체의 제조 방법 및 이로부터 제조된 공액 디엔계 및 방향족 비닐계의 공중합체를 포함하는 타이어
EP3891157A4 (en) 2018-12-05 2022-08-31 Merck Sharp & Dohme Corp. 4-AMINO- OR 4-ALKOXY-SUBSTITUTED ARYLSULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATE SODIUM CHANNELS
WO2020118036A1 (en) 2018-12-06 2020-06-11 The Children's Medical Center Corporation Antibacterial compounds and uses thereof
WO2020123675A1 (en) 2018-12-11 2020-06-18 Duke University Compositions and methods for the treatment of cancer
US20220073471A1 (en) 2019-01-04 2022-03-10 Jiangsu Hengrui Medicine Co., Ltd. 6-oxo-1,6-dihydropyridazine derivative, preparation method therefor and medical use thereof
US12440481B2 (en) 2019-01-10 2025-10-14 Vertex Pharmaceuticals Incorporated Esters and carbamates as modulators of sodium channels
WO2020146682A1 (en) 2019-01-10 2020-07-16 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
CN111434655A (zh) 2019-01-15 2020-07-21 武汉朗来科技发展有限公司 溶血磷脂酸受体拮抗剂及其制备方法
WO2020152079A1 (en) 2019-01-22 2020-07-30 Merck Patent Gmbh Method for the preparation of a liquid crystal polymer film
TW202043200A (zh) 2019-01-25 2020-12-01 大陸商江蘇恆瑞醫藥股份有限公司 ２－側氧基－１，２－二氫吡啶類衍生物、其製備方法及其在醫藥上的應用
AU2019427489B2 (en) 2019-01-28 2025-03-13 Mitochondria Emotion, Inc. Mitofusin activators and methods of use thereof
WO2020160225A1 (en) 2019-01-30 2020-08-06 Ohio State Innovation Foundation ESTROGEN RECEPTOR BETA (ERβ) AGONISTS FOR THE TREATMENT OF FIBROTIC CONDITIONS
US20220160705A1 (en) 2019-03-20 2022-05-26 Cornell University Methods for controlling prostaglandin-mediated biological processes
WO2020191501A1 (en) 2019-03-27 2020-10-01 Algernon Pharmaceuticals Inc. Methods and uses of bemithyl and derivatives for treating lung disease, fatty liver disease, and kidney disorders
CN113785032A (zh) 2019-04-30 2021-12-10 默克专利股份有限公司 反应性介晶
WO2020228922A1 (de) 2019-05-10 2020-11-19 Wacker Chemie Ag Kationische germanium(ii)-verbindungen, verfahren zu deren herstellung und deren verwendung als katalysator in der hydrosilylierung
JP2022532718A (ja) 2019-05-14 2022-07-19 メタボメッド リミテッド Ａｃｓｓ２阻害剤およびその使用方法
WO2020251974A1 (en) 2019-06-10 2020-12-17 Kymera Therapeutics, Inc. Smarca inhibitors and uses thereof
BR112021025317A2 (pt) 2019-06-21 2022-03-15 Bayer Ag Tienilhidroxiisoxazolinas e derivados das mesmas
MX2021015605A (es) 2019-06-27 2022-02-16 Glaxosmithkline Ip Dev Ltd Compuestos 2,3-dihidroquinazolin como inhibidores nav1.8.
WO2021001739A1 (en) 2019-07-02 2021-01-07 Effector Therapeutics, Inc. Translational enhancers and related methods
CN112300051A (zh) 2019-07-31 2021-02-02 明慧医药（上海）有限公司 一种选择性钠通道调节剂及其制备和应用
CN112300069A (zh) 2019-07-31 2021-02-02 明慧医药（上海）有限公司 一种选择性钠通道调节剂及其制备和应用
WO2021032074A1 (zh) 2019-08-19 2021-02-25 江苏恒瑞医药股份有限公司 苯甲酰胺稠芳环类衍生物、其制备方法及其在医药上的应用
CN112390745B (zh) 2019-08-19 2022-10-21 江苏恒瑞医药股份有限公司 吡啶烟酰胺类衍生物、其制备方法及其在医药上的应用
CN112409331B (zh) 2019-08-21 2024-02-20 上海翰森生物医药科技有限公司 杂环类衍生物抑制剂、其制备方法和应用
CN112441969A (zh) 2019-08-30 2021-03-05 明慧医药（上海）有限公司 一种选择性钠通道调节剂及其制备和应用
BR112022004495A8 (pt) 2019-09-12 2023-04-18 Jiangxi Jemincare Group Co Ltd Compostos oxinitreto de piridina, composição farmacêutica compreendendo os mesmos e usos dos mesmos
WO2021074357A1 (en) 2019-10-17 2021-04-22 Enyo Pharma Thiophene derivatives for use in treating portal inflammation and fibrosis
BR112022010924A2 (pt) 2019-12-06 2022-09-06 Vertex Pharma Tetra-hidrofuranos substituídos como moduladores de canais de sódio
JP2023507787A (ja) 2019-12-20 2023-02-27 サムヤン ホールディングス コーポレイション オラパリブの溶解度及び生体利用効率が改善された組成物
CN111217776A (zh) 2020-01-19 2020-06-02 中国人民解放军军事科学院军事医学研究院 含苯并杂环结构的酰胺衍生物、组合物和应用
WO2021239117A1 (en) 2020-05-28 2021-12-02 Cullgen (Shanghai) , Inc. Modified proteins and protein degraders
CA3183948A1 (en) 2020-06-10 2021-12-16 Amgen Inc. Heteroalkyl dihydroquinoline sulfonamide compounds
JP2021195367A (ja) 2020-06-10 2021-12-27 アムジエン・インコーポレーテツド シクロプロピルジヒドロキノリンスルホンアミド化合物
JP7739051B2 (ja) 2020-06-10 2025-09-16 アムジエン・インコーポレーテツド シクロブチルジヒドロキノリンスルホンアミド化合物
US12516046B2 (en) 2020-06-17 2026-01-06 Merck Sharp & Dohme Llc 2-oxo-oxazolidine-5-carboxamides as NAV1.8 inhibitors
CN115697327A (zh) 2020-06-17 2023-02-03 默沙东有限责任公司 作为nav1.8抑制剂的5-氧代-吡咯烷-3-甲酰胺
US11802122B2 (en) 2020-06-17 2023-10-31 Merck Sharp & Dohme Llc 2-oxoimidazolidine-4-carboxamides as NAv1.8 inhibitors
GB202011996D0 (en) 2020-07-31 2020-09-16 Adorx Therapeutics Ltd Antagonist compounds
EP4196482B1 (en) 2020-08-14 2025-10-01 SiteOne Therapeutics, Inc. Non-hydrated ketone inhibitors of nav1.7 for the treatment of pain
WO2022037647A1 (zh) 2020-08-19 2022-02-24 江苏恒瑞医药股份有限公司 一种选择性Nav抑制剂的结晶形式及其制备方法
TW202214259A (zh) 2020-08-19 2022-04-16 大陸商江蘇恆瑞醫藥股份有限公司 一種選擇性ＮａＶ抑制劑的前藥及其晶型
CN111808019B (zh) 2020-09-08 2020-11-27 上海济煜医药科技有限公司 一种并环化合物及其应用
US20230340329A1 (en) 2020-09-24 2023-10-26 Merck Patent Gmbh Polymerizable liquid crystal material and polymerized liquid crystal film
WO2022070048A1 (en) 2020-09-29 2022-04-07 Cadila Healthcare Limited Novel amide derivatives
EP4232020A4 (en) 2020-10-21 2024-08-07 Kura Oncology, Inc. Treatment of hematological malignancies with inhibitors of menin
CN112225695B (zh) 2020-12-15 2021-03-02 上海济煜医药科技有限公司 一种氮氧化合物及其制备方法和用途
CN112457294B (zh) 2021-01-27 2021-06-04 上海济煜医药科技有限公司 一种作为NaV1.8阻滞剂的化合物及其制备方法和用途
SMT202500481T1 (it) 2021-06-04 2026-01-12 Vertex Pharma N-(idrossialchil(etero)aril)tetraidrofuran carbossammidi come modulatori di canali del sodio

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020526561A (ja) * 2017-07-11 2020-08-31 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ ナトリウムチャネルのモジュレーターとしてのカルボキサミド
WO2020092667A1 (en) * 2018-11-02 2020-05-07 Merck Sharp & Dohme Corp. 2-amino-n-heteroaryl-nicotinamides as nav1.8 inhibitors

Also Published As

Publication number Publication date
FI4347031T3 (fi) 2025-12-19
US11827627B2 (en) 2023-11-28
CA3221259A1 (en) 2022-12-08
ECSP23095485A (es) 2024-02-29
ES3058787T3 (en) 2026-03-12
US20240182455A1 (en) 2024-06-06
RS67577B1 (sr) 2026-01-30
CR20230586A (es) 2024-05-07
US20250353836A1 (en) 2025-11-20
CL2023003625A1 (es) 2024-05-24
DK4347031T3 (da) 2025-12-01
LT4347031T (lt) 2026-01-12
PT4347031T (pt) 2026-01-19
HRP20251504T1 (hr) 2026-01-02
EP4347031A1 (en) 2024-04-10
UY39800A (es) 2023-01-31
US20230009251A1 (en) 2023-01-12
EP4699607A2 (en) 2026-02-25
EP4347031B1 (en) 2025-10-29
DOP2023000267A (es) 2024-03-28
MX2023014378A (es) 2023-12-15
GEAP202416430A (en) 2024-03-25
CN117794920A (zh) 2024-03-29
SMT202500481T1 (it) 2026-01-12
CO2023017899A2 (es) 2023-12-29
TW202313593A (zh) 2023-04-01
KR20240031300A (ko) 2024-03-07
AU2022284886A1 (en) 2023-11-30
MD4347031T2 (ro) 2026-03-31
JOP20230316B1 (ar) 2025-10-01
AR126073A1 (es) 2023-09-06
IL308953A (en) 2024-01-01
US12258333B2 (en) 2025-03-25
PL4347031T3 (pl) 2026-02-23
SI4347031T1 (sl) 2026-01-30
PE20241335A1 (es) 2024-07-03
MA64853B1 (fr) 2025-11-28
WO2022256622A1 (en) 2022-12-08

Similar Documents

Publication Publication Date Title
EP4347031B1 (en) N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels
US11919887B2 (en) Substituted tetrahydrofurans as modulators of sodium channels
US20240294512A1 (en) Hydroxy and (halo)alkoxy substituted tetrahydrofurans as modulators of sodium channels
JP2024520646A (ja) ナトリウムチャネルのモジュレーターとしてのｎ－（ヒドロキシアルキル（ヘテロ）アリール）テトラヒドロフランカルボキサミド類似体
JP2024522293A (ja) ナトリウムチャネルのモジュレーターとしての置換テトラヒドロフラン類似体
EP4347032A1 (en) Substituted tetrahydrofuran-2-carboxamides as modulators of sodium channels
OA21895A (en) N-(HydroxyalkyI (Hetero) Aryl) Tetrahydrofuran carboxamides as modulators of sodium channels.
EA051527B1 (ru) N-(гидроксиалкил(гетеро)арил)тетрагидрофуранкарбоксамиды в качестве модуляторов натриевых каналов
HK40080163B (en) Substituted tetrahydrofurans as modulators of sodium channels
HK40080163A (en) Substituted tetrahydrofurans as modulators of sodium channels

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250603

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250603

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250623

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260225

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260226